Droxidopa
23651-95-8N[C@H](C(=O)O)[C@H](O)c1ccc(O)c(O)c1QXWYKJLNLSIPIN-JGVFFNPUSA-NDroxidopa is a serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension. It has a role as an antihypertensive agent, a prodrug and a vasoconstrictor agent. It is a L-tyrosine derivative and a member of catechols.
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Warning
H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]
P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 42 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Warning
H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]
Skin Irrit. 2 (100%)
Skin Irrit. 2 (100%)
Liver test abnormalities have not been reported in patients taking droxidopa, but the agent has had limited clinical use. There were no episodes of clinically apparent liver injury reported in the preregistration trials of droxidopa, and since its approval there have been no published reports of droxidopa hepatotoxicity. Thus, liver injury from droxidopa is likely to be rare, if it occurs at all.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Droxidopa
vNo-DILI-concern
0
No match
DOI:10.1016/j.drudis.2016.02.015
C - Cardiovascular system
QC - Cardiovascular system
Droxidopa is an orally active synthetic precursor of norepinephrine that increases the deficient supply of norepinephrine in patients with NOH, thereby improving orthostatic blood pressure and alleviating associated symptoms of lightheadedness, dizziness, blurred vision, and syncope through the induction of tachycardia (increased heart rate) and hypertension.
Droxidopa crosses the blood-brain barrier where it is converted to norepinephrine via decarboxylation by L-aromatic-amino-acid decarboxylase. Norephinephrine acts at alpha-adrenergic receptors as a vasoconstrictor and at beta-adrenergic receptors as a heart stimulator and artery dilator.
J7A92W69L7
DROXIDOPA
Chemical Structure [CS] - Catecholamines
Physiologic Effects [PE] - Increased Blood Pressure
The physiologic effect of droxidopa is by means of Increased Blood Pressure.
DROXIDOPA
Oral bioavailability is 90%.
Droxidopa is mainly excreted in the urine, with the main metabolite being 3-O-methyldihydroxyphenylserine.
23651-95-8、3916-18-5DTXSID201017236CHEMBL2103827CHEBI:31524化学的特性Off-White Solid
用途ノルアドレナリン前駆体物質 です。芳香族L-アミノ酸脱炭酸酵素により、 ノルアドレナリンに変換されます。
用途ノルアドレナリン前駆体物質 です。芳香族L- アミノ酸脱炭酸酵素により、 ノルアドレナリンに変換されます。
説明Droxidopa is a synthetic amino acid precursor of (-)-norepinephrine which is absorbed from the gut and metabolized to norepinephrine. In Parkinsonian patients, droxidopa added to existing levodopa/decarboxylase inhibitor therapy produces significant improvements in retropulsion, dysarthria and muscular rigidity refractory to other treatments; however, tremor was unaffected.
使用The L-threo-form Droxidopa. A synthetic amino acid precursor of Norepinephrine (N674500). Antiparkinsonian.
一般的な説明L-DOPS, also called L-threo 3,4-Dihydroxyphenylserine or droxidopa is a catecholamine. L-DOPS has many clinical advantages and may be useful for treating norepinephrine deficiency. It is used for treating neurogenic orthostatic hypotension and improves norepinephrine levels. L-DOPS mediates reduction of amyloid plaques and could have a therapeutic potential for treating amyloid pathology.
定義ChEBI: A serine derivative that is L-serine substituted at the beta-position by a 3,4-dihydroxyphenyl group. A prodrug for noradrenalone, it is used for treatment of neurogenic orthostatic hypotension